Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Ultragenyx Pharmaceutical Q3 2026 Results: Net Loss of $118M, Loss Narrows

Ultragenyx Pharmaceutical Inc. reported its quarterly results for the period ending September 30, 2026, highlighting continued revenue growth from its commercialized products and ongoing investment in its clinical pipeline. The company maintained its focus on rare and ultra-rare disease treatments while managing operating expenses in line with strategic objectives.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue173.0160.0
Profit before tax-127.0-179.0
Net income-118.0-180.0
EPS (diluted, $ a share)$-1.16$-1.81

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+8.1%
Operating margin-63.6%
Source

10-Q filed with the SEC, NASDAQ: RARE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Ultragenyx Pharmaceutical Inc.: key numbers

Share price
$16.70Close, Nov 17
Market cap
$1.7B
Shares outstanding
101.92MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ultragenyx Pharmaceutical Inc.

All →
4:08 PM ET 8-K
Financial Results

Ultragenyx Pharmaceutical Financial Results

Ultragenyx reported Q3 2026 total revenue of $173 million and a net loss of $118 million, while announcing a major restructuring plan to reduce its workforce by 20%. The company also confirmed the sale of two Priority Review Vouchers for $413 million and reaffirmed its 2026 revenue guidance and 2027 profitability targets.

Term
Q3 2026

“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products. With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”

Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx
1:49 PM ET Form 4
Insider Selling

Ultragenyx Pharmaceutical CFO Howard Horn Sells $108K of Stock

Howard Horn, CFO, sold 7,066 shares of Ultragenyx Pharmaceutical Inc. at $15.27 a share, worth $108K in total on Oct 15, 2026. Shares held after the trade: 89,229 (-7.3%).

Value
$108K
Shares
7,066
Price
$15.27
Role
CFO
Holding change
-7.3%
Trade date
Oct 15, 2026
9:00 AM ET 8-K
Court & Legal Update

Ultragenyx Pharmaceutical Court & Legal Update

Ultragenyx and Baylor Research Institute entered into a settlement agreement with Navinta LLC to resolve patent litigation regarding DOJOLVI® (triheptanoin). Under the agreement, Navinta is granted a non-exclusive, royalty-free license to market a generic version of the drug starting January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted.

Counterparty
Navinta LLC
9:01 AM ET 8-K
Divestiture

Ultragenyx Pharmaceutical Divestiture for $203M

Ultragenyx Pharmaceutical Inc. entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash. The PRV was recently awarded by the FDA following the approval of FAYUVI (UX111) for the treatment of Sanfilippo syndrome Type A. The transaction is subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino Act.

Value
$203M
9:00 AM ET 8-K
Divestiture

Ultragenyx Pharmaceutical Divestiture for $210M

Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million in cash. The PRV was recently awarded by the FDA following the approval of GENGLYCOS for the treatment of glycogen storage disease type Ia. Under a prior agreement, the company will pay 20% of the gross proceeds from this sale to the NIH.

Value
$210M
3:57 PM ET 8-K
Regulatory Approval

Ultragenyx Pharmaceutical Regulatory Approval

The FDA has granted standard full approval for Ultragenyx's FAYUVI (rebisufligene etisparvovec-hopf), the first-ever approved treatment for Sanfilippo syndrome Type A (MPS IIIA). This marks the company's second gene therapy approval and resulted in the receipt of a Priority Review Voucher.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.